Leela Barham

Rises in non-submissions to NICE: do they matter?

https://pharmaphorum.com/views-analysis-market-access/rises-in-non-submissions-to-nice-do-they-matter/

Getting the most out of technical engagement with NICE

https://pharmaphorum.com/views-analysis-market-access/getting-the-most-out-of-technical-engagement-with-nice/

Market access in the time of COVID-19

https://deep-dive.pharmaphorum.com/magazine/market-access-2020/market-access-in-the-time-of-covid-19/

COVID-19 puts NHS’ app library to the test

https://pharmaphorum.com/views-and-analysis/covid-19-puts-nhs-app-library-to-the-test/

Harmonised health technology assessment in Europe? There’s a long way to go

https://pharmaphorum.com/views-analysis-market-access/harmonised-health-technology-assessment-in-europe-theres-a-long-way-to-go/

Has the UK been best place in the world to invest in life sciences?

https://pharmaphorum.com/views-and-analysis/uk-best-place-world-invest-life-sciences/

Could the PPRS support a changing growth and innovation agenda?

https://pharmaphorum.com/views-and-analysis/pprs-support-changing-growth-innovation-agenda/

Bureaucracy and duplication: the reality of the PPRS

https://pharmaphorum.com/views-and-analysis/bureaucracy-duplication-pprs/

Improved access? The reality of the PPRS

https://pharmaphorum.com/views-and-analysis/improved-access-reality-pprs/

1 2 3

Close in 10 seconds

Pharmaphorum.com

Search